Get started
Author

Maura Camozzi

Role of the soluble pattern recognition receptor PTX3 in vascular biology
2007 · Marco Presta, Maura Camozzi, et al. · Journal of Cellular and Molecular Medicine · 190
PDF
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis
2004 · Marco Rusnati, Maura Camozzi, et al. · Blood · 188
Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3
2006 · Maura Camozzi, Marco Rusnati, et al. · Journal of Biological Chemistry · 110
PDF
Pentraxin 3 Inhibits Fibroblast Growth Factor 2–Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo
2005 · Maura Camozzi, Serena Zacchigna, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 105
Heparin Derivatives as Angiogenesis Inhibitors
2003 · M. Presta, D. Leali, et al. · Current Pharmaceutical Design · 103
A pro‐inflammatory signature mediates FGF2‐induced angiogenesis
2008 · Germán Andrés, Daria Leali, et al. · Journal of Cellular and Molecular Medicine · 78
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
2016 · G. Jerusalem, G. Mariani, et al. · Annals of Oncology · 76
PDF
Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist
2009 · Patrizia Alessi, Daria Leali, et al. · European Cytokine Network · 76
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
2017 · Heikki Joensuu, Jean-Yves Blay, et al. · British Journal of Cancer · 44
Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists
2004 · Marco Presta, Pasqua Oreste, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 36
PDF
Inhibition of intra‐ and extra‐cellular Tat function and HIV expression by pertussis toxin B‐oligomer
2004 · Chiara Rizzi, Massimo Alfano, et al. · European Journal of Immunology · 12
Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04)
2015 · JERUSALEM, Guy, Mariani, Gabriella, et al. · ORBi (University of Liège) · 3
Phase 2 Trial to Evaluate the Efficacy and Safety of Dovitinib in Patients (Pts) with Gastrointestinal Stromal Tumor (Gist) Refractory and/or Intolerant to Imatinib (Im)
2014 · H. Joensuu, J-Y. Blay, et al. · Annals of Oncology · 3
Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)
2015 · Guy Jerusalem, Gabriella Mariani, et al. · Cancer Research · 2
Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors
2005 · Marco Presta, Daria Leali, et al. · Frontiers in Medicinal Chemistry - Online · 1
Abstract P4-13-10: Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC) in the BALLET trial (CRAD001YIC04)
2016 · EM Ciruelos, G Jerusalem, et al. · Cancer Research
Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety form BALLET (CRAD001YIC04)
2016 · Patrick Neven, Daniele Generali, et al. · Open Repository and Bibliography (University of Liège)
1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)
2015 · P. Neven, D. Generali, et al. · European Journal of Cancer
Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors
2010 · Marco Presta, Daria Leali, et al. · BENTHAM SCIENCE PUBLISHERS eBooks
Works count: 20
Citation count: 1,027
H-index: 11
I10-index: 11
Year
Topic
Type